Syntrix Pharmaceuticals

Executive Summary

Syntrix Pharmaceuticals is a private, clinical-stage biopharmaceutical company based in Auburn, Washington, founded in 2000. The company employs a convergent science strategy to develop novel small molecule therapeutics targeting immuno-oncology, pain, and autoimmunity—areas with significant unmet medical needs. Its lead pipeline includes a first-in-class oral small molecule immunomodulator for cancer immunotherapy, currently in Phase 2 clinical trials for solid tumors. Syntrix also has preclinical programs in neuropathic pain and autoimmune disorders, leveraging proprietary platforms to address key disease pathways. While the company is not yet revenue-generating, it has demonstrated proof-of-concept in early studies and is actively seeking strategic partnerships to advance its assets through development.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 data readout for lead immuno-oncology candidate35% success
• Q1 2027IND filing for new autoimmune program60% success
• Q2 2027Potential licensing or collaboration deal for pain pipeline40% success